Agios Pharmaceuticals Stock News

Agios has a February 17 PDUFA for mitapivat in PK deficiency.

– Company Expects to Receive FDA Regulatory Decision for Mitapivat as a Potential Treatment for Adults with PK Deficiency in February –

Investors are keenly aware that growth stocks have beaten value stocks five years in a row. So what am I going to recommend today?

Big pharma companies and small biotechs alike emerged from the key American Society of Hematology conference as big winners.

CAMBRIDGE, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced th

CAMBRIDGE, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced that the company is scheduled to present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 7:30 a.m. ET.

CAMBRIDGE, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced that

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Research analysts at Oppenheimer issued their Q1 2022 earnings per share estimates for Agios Pharmaceuticals in a report released on Wednesday, December 15th. Oppenheimer analyst M. Breidenbach expects that the biopharmaceutical company will post earnings of ($1.53) per share for the quarter. Oppenheimer also issued estimates for Agios Pharmaceuticals Q2 []

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have been assigned a consensus recommendation of “Hold” from the eleven ratings firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating on the company. […]

Agios Pharmaceuticals Inc (NASDAQ: AGIO ) reported new data from the ongoing long-term extension study assessing the duration of effects of mitapivat in adults with pyruvate kinase (PK) deficiency. Data were featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. Long-term extension data demonstrate that

Agios Pharmaceuticals Inc (NASDAQ: AGIO) reported new data from the ongoing long-term extension study assessing the duration of effects of mitapivat in adults with pyruvate kinase (PK) deficiency.

– Additional Data Presented at ASH Support the Potential of Mitapivat to Improve Ineffective Erythropoiesis and Iron Overload and Stabilize Bone Mineral Density in PK Deficiency Patients –

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) reached a new 52-week low on Monday . The stock traded as low as $29.30 and last traded at $29.67, with a volume of 9098 shares trading hands. The stock had previously closed at $29.58. Several equities research analysts recently weighed in on the stock. SVB Leerink reduced their target price […]

– Global Phase 3 ENERGIZE and ENERGIZE-T Studies of Mitapivat in Transfusion-dependent and Non-transfusion-dependent α- and β-Thalassemia Initiated –

– Data Underscore Potential of Mitapivat to Provide Clinically Meaningful Outcomes for Patients –